Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses

Identification, optimization and use of cryptic HLA-A24 epitopes for immunotherapy

Compositions and Methods for Modulating a Cytotoxic T Lymphocyte Immune Response

Antiviral vaccines with improved cellular immunogenicity

Multiple antigen delivery system using hepatitis E virus-like particle

Peptidic antigen that induces antibody recognizing three-dimensional structure of HIV and method for synthesizing same

Albumin fusion proteins

Biochemically stabilized HIV-1 ENV trimer vaccine

HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES

Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells

Modified HIV-1 Envelope Proteins

INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS

Antigen delivery vectors and constructs

Conformationally stabilized HIV envelope immunogens

ANTIGENIC CLOAKING AND ITS USE

Method for ameliorating pain by modification of NMDA receptors through inhibition of Src

LIPOPEPTIDE INHIBITORS OF HIV-1

Immunogenic compositions for inducing an immune response to HIV

Compositions and methods for the treatment of viral infections

Gp41 antigens

Splitting GP41

Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof

HIV-1 Envelope Polypeptides for HIV Vaccine

Nucleic acids encoding mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

HIV-1 Immunogenic Compositions

Human immunodeficiency virus and uses thereof

FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS

HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV

Bifunctional molecules for inactivating HIV and blocking HIV entry

HIV-1 envelope glycoprotein

Recombinant Protein Bodies as Immunogen-Specific Adjuvants

Chimeric HIV Antigens

Covalently linked complexes of HIV TAT and ENV PROTEINS

Identification, optimization and use of cryptic HLA-B7 epitopes for immunotherapy

MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF

Modified peptide that reduces pain in peripheral neuropathy

Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof

HIV-1 Envelope Based Fragments

Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies

POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

NON-INTEGRATING LENTI/ADENO-ASSOCIATED VIRUS HYBRID VECTOR SYSTEM

Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides

Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen

METHOD OF MAKING A VACCINE

COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS

Anti-HIV vaccine constructed based on amino acid mutations in attenuated live EIAV vaccine

CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE

POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS

Synthetic gene construct coding for an HIV1 GAG and use thereof for obtaining anti-HIV-1 vaccines

LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION

Tat DNA sequences, gene constructs, vaccine and processes thereof

CONJUGATE OF AN ANTIBODY AGAINST CCR5 AND AN ANTIFUSOGENIC PEPTIDE

METHODS OF TREATING AND PROTECTING AGAINST HUMAN IMMUNODEFICIENCY VIRUS

MVA expressing modified HIV envelope, GAG, and POL genes

COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION

SARS vaccine compositions and methods of making and using them

Methods of Eliciting Broadly Neutralizing Antibodies Targeting HIV-1 GP41

Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom

VIRAL VECTORS FOR DELIVERING VACCINES FOR HIV AND OTHER INFECTIOUS DISEASES

Efficient production of peptides

Viral chemokine-antigen fusion proteins

VIRUS-LIKE PLATFORM FOR RAPID VACCINE DISCOVERY

MVA expressing modified HIV envelope, gag, and pol genes

Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions

Antigen constructs useful in the detection and differentiation of antibodies to HIV

HIV-1 GP41 neutralization domain and use thereof

Fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

Method of inhibiting HIV-1 binding to genital epithelia using V3 loop-specific peptides and GP340-specific antibodies

Reverse Transfection Of Cell Arrays For Structural And Functional Analyses Of Proteins

Soluble stabilized trimeric hiv env proteins and uses thereof

Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface

LONG LASTING ANTI-ANGIOGENIC PEPTIDES

EPITOPE TESTING USING SOLUBLE HLA

Expression of HIV polypeptides and production of virus-like particles

HIV POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM BOTSWANA MJ4

Recombinant Double-Stranded RNA Phage, and Use of the Same

Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices

SUGAR IMMUNOGENS

Chimeric HIV Env proteins comprising CD4 mini-proteins or CD4 mimetics that are capable of inducing neutralizing antibody responses against cryptic Env epitopes

METHOD FOR PRODUCTION OF N36-BINDING PEPTIDE

HIV COMBINATION VACCINE AND PRIME BOOST

Albumin fusion proteins

Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties

Influenza hemagglutinin and neuraminidase variants

POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF

HIV-1 envelope glycoprotein oligomer and methods of use

Chimeric HIV-1 Glycoproteins and Their Biological Applications

METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION

IMMUNOGENICITY USING A COMBINATION OF DNA AND VACCINIA VIRUS VECTOR VACCINES

MULTICOMPONENT VACCINE

COMBINED MUCOSAL AND PARENTERAL IMMUNIZATION AGAINST HIV

CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS

ANIMAL MODEL FOR HIV INDUCED DISEASE

Method

NOVEL METHODS OF SYNTHESIS FOR THERAPEUTIC ANTIVIRAL PEPTIDES

COMPOSITION AND METHOD FOR TREATING VIRAL INFECTION

Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV

DIASTEREOMERIC PEPTIDES USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY

Subgenomic replicons of the flavivirus dengue

CONSTRAINED HIV ENVELOPE-BASED IMMUNOGEN THAT SIMULTANEOUSLY PRESENTS RECEPTOR AND CORECEPTOR BINDING SITES

Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120

Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction

Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif

Recoding method that removes inhibitory sequences and improves HIV gene expression

Virus-like particles comprising chimeric human immunodeficiency virus (HIV)/mouse mammary tumor virus (MMTV) envelopes

Five-helix protein

Therapeutic peptides and vaccines

Non-M, non-O HIV-1 strains, fragments and uses

Antigen delivery vectors and constructs

Mannose immunogens for HIV-1

Antigen delivery vectors and constructs

HPV vaccines and methods for using the same

METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES

Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes

Determination of a specific immunoglobulin using multiple antigens

ANTI-HIV IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

HIV vaccines based on Env of multiple clades of HIV

Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women

PURIFICATION AND CHARACTERIZATION OF SOLUBLE MHC PROTEINS

ACUTTE TRANSMITTED HIV ENVELOPE SIGNATURES

Altered Immunogenic Landscape in HIV-1 Envelope Proteins

Method of making biologically active alpha-beta peptides

Immunoenhancer-linked oligomeric HIV envelope peptides

VACCINE COMPOSITIONS AGAINST INFECTIOUS PATHOLOGIES FOR MAMMALS

Modified human immunodeficiency virus clade C envelope polypeptides obtained from a zambian isolate

Method for Shielding Functional Sites or Epitopes on Proteins

MODIFIED HIV ENV POLYPEPTIDES

Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response

Chimeric influenza virus-like particles

Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4

Methods of using Fc-cytokine fusion proteins

MULTIMERISED HIV FUSION INHIBITORS

Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids

Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates

Recombinant vectors based on the modified vaccinia ankara virus (MVA) as preventive and therapeutic vaccines against AIDS

Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain

Polycistronic HIV vector constructs

Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors

Antigen constructs useful in the detection and differentiation of antibodies to HIV

AIDS Vaccine Based on Replicative Vaccinia Virus Vector

TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY

Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus

CONJUGATES COMPRISED OF POLYMER AND HIV gp-41-DERIVED PEPTIDES AND THEIR USE IN THERAPY

Combination Approaches For Generating Immune Responses

Coiled-coil lipopeptide helical bundles and synthetic virus-like particles

Tetramers

VACCINE

Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions

Recombinant double stranded RNA nucleocapsid and use of the same

HIV-1 latency model for high throughput screening

Modified HIV Env polypeptides

Bifunctional molecules for inhibiting HIV entry

ADJUVANT

Method of using adenoviral vectors to induce an immune response

Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens

Nucleic acids encoding modified South African HIV-1 subtype C gag proteins

HIV-I GP41 FUSION PEPTIDES FOR IMMUNOMODULALTION

exotoxin A-like chimeric immunogens

Modified HIV-1 group M cyclic gp41 peptides and their use in the detection of anti-HIV-1 antibodies

Vaccines containing the hiv tat protein as an adjuvant for the enhancement of cytotoxic t-cell responses

HIV VACCINE FORMULATIONS

Multilayer films, coatings, and microcapsules comprising polypeptides

Modified HIV-1 envelope proteins

HIV Inhibiting Proteins

Methods and compositions for immunization against hiv

Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid

Simian adenovirus vectors and methods of use

Immunogens for Vaccines Against Antigenically Variable Pathogens and Diseases

Vaccines against aids comprising cmv/r-nucleic acid constructs

Epitope-enhancement of a human cd4 hiv epitope

HIV polynucleotides and polypeptides derived from Botswana MJ4

CHIMERIC HIV FUSION PROTEINS AS VACCINES

Virosome-like vesicles comprising gp41-derived antigens

Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens

Conformationally stabilized HIV envelope immunogens and triggering HIV-I envelope to reveal cryptic V3-loop epitopes

Influenza antigen delivery vectors and constructs

Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating an Immune Response

Methods for removing anti-MHC antibodies from a sample

Modifications of HIV Env, Gag, and Pol enhance immunogenicity for genetic immunization

Influenza Hemagglutinin And Neuraminidase Variants

Albumin-Fused Anti-Angiogenesis Peptides

Genetic constructs and compositions comprising RRE and CTE and uses thereof

Recombinant protein production in a human cell

DNA-BASED VACCINATION OF RETROVIRAL-INFECTED INDIVIDUALS UNDERGOING TREATMENT

Molecular scaffolds for HIV-1 immunogens

Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain

Fluorescence resonance energy transfer screening assay for the identification of HIV-1 envelope glycoprotein-medicated cell

Peptide-complement conjugates

Immunizing Against HIV Infection

Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site

Cell compositions useful for cell-based FRET assays for clostridial toxins

Composition and method for enhancing immune response

Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens

HIV fusion inhibitor peptides with improved biological properties

NOVEL USE

Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity

Virus derived antimicrobial peptides

Albumin Fusion Proteins

Method of making immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane

Method of inducing an immune response in a host by administering immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane

Immunogen comprising the HIV GP120 V3 loop in a conformation that induces broadly neutralizing antibodies

Albumin Fusion Proteins

GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE

CYSTEIC ACID DERIVATIVES OF ANTI-VIRAL PEPTIDES

PSEUDOMONAS EXOTOXIN A-LIKE CHIMERIC IMMUNOGENS FOR ELICITING A SECRETORY IGA-MEDIATED IMMUNE RESPONSE

Virus coat protein/receptor chimeras and methods of use

Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof

DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40

MVA expressing modified HIV envelope, gag, and pol genes

Immunological compositions

Virus-like platform for rapid vaccine discovery

Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications

Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof

Protein Delivery System

TSG101-GAG INTERACTION AND USE THEREOF

Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Immunizing compositions comprising recombinant attenuated self-replicating viral RNA replicons encoding an epitope obtained from the HIV-1 matrix protein myrstate binding site

Conjugate of an antibody against CCR5 and an antifusogenic peptide

Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein

Conjugate of an antibody against CD4 and antifusogenic peptides

Advanced genetic vaccines

SARS Vaccine Compositions and Methods of Making and Using Them

Inhibitors of Infection

Human immunodeficiency virus integrase—Transportin—SR protein—protein interactions

Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs

Renta: an HIV immunogen and uses thereof

Modified Bacteriophage Vectors and Uses Thereof

Covalently-linked complexes of HIV Tat and Env proteins

HIV vaccines based on Env of multiple clades of HIV

Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus

INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE

T4 bacteriophage bound to a substrate

Recombinant protein production in a human cell

Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex

Method

Soluble chimeric peptide inhibitors of HIV entry comprising an IZ trimeric coiled-coil peptide and HIV gp41 N-helix coiled-coil peptide

Lentiviral packaging constructs

AIDS vaccines

Expression of HIV polypeptides and production of virus-like particles

Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens

Mycobacteria expressing HIV-1 and malaria antigens

Hetero-Oligomeric Hiv Envelope Proteins

Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism

Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Albumin fusion proteins

CELLULAR IMMUNITY TEST WITH PEPTIDES ATTACHED TO A SOLID SUPPORT

Immunogen

Soluble and stabilized trimeric form of gp41 polypeptides

Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists

VACCINE

LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION

Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes

Immunodeficiency recombinant poxvirus

METAL CHELATE-LABELLED PEPETIDES

Process for producing stable HIV Th-CTL peptides

Sugar immunogens

LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION

Recombinant HBsAg virus-like particles containing polyepitopes of interest, their production and use

Albumin Fusion Proteins

Albumin fusion proteins comprising insulin polypeptides

Albumin Fusion Proteins

HIV capsid assembly-associated compositions and methods

G-CSF-albumin fusion proteins

Albumin fusion proteins

Identification of the Precise Amino Acid Sequence of the Epitope Recognized by the Potent Neutralizing Human Anti-Hiv-1 Monoclonal Antibody Igg1b12

Methods of inducing mucosal immunity

Epitope escape mutations

Directional induction of immune response by co-administration of antigens with chemokines

VACCINE COMPRISING GP120 AND NEF AND/OR TAT FOR THE IMMUNIZATION AGAINST HIV

Diastereomeric Peptides Useful as Inhibitors of Membrane Protein Assembly

POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE B POLYPEPTIDES, POLYPEPTIDES, AND USES THEREOF

Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades

Antigen constructs useful in the detection and differentiation of antibodies to HIV

Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use

Antigen constructs useful in the detection and differentiation of antibodies to HIV

HIV-1 Clade A consensus sequences, antigens, and transgenes

Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2

Non-integrative and non-replicative lentivirus, preparation and uses thereof

Cytoplasmic Localization Dna and Rna

Interacting site for gp41 on gp120 of hiv-1

Poxvirus Vector Encoding Retrovirus (Eg Hiv) And Cytokine

Compounds For Specific Viral Target

A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines

Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies

Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen

Lentiviral packaging constructs

Polynucleotides encoding modified HIV-1 gp41 membrane polypeptides

Immunogenic proteoliposomes, and uses thereof

Mva Vaccines

Retrovirus from the HIV group and its use

Albumin fusion proteins

VACCINE

Immunomodulating Compositions, Uses Therefore and Processes for Their Production

Albumin fusion proteins

Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity

HIV-1 glycopeptides and derivatives; preparation and applications thereof

Lipid-Mediated Polynucleotide Administration to Deliver a Biologically Active Peptide and to Induce a Cellular Immune Response

Synthesis using peptide intermediate fragments

Method of Using Adenoviral Vectors to Induce an Immune Response